Search results
Results From The WOW.Com Content Network
Novartis continues transformation into a leading medicines company with completion of the Alcon spin-off. Read More
Exactly eight years into its full ownership of Alcon, Novartis will officially say goodbye to the eye care business on April 9. The new Alcon shares will be listed on the Swiss Exchange and...
Novartis has a catalyst-rich pipeline with 10 potential blockbuster launches planned in the next two years, and 20 additional potential blockbusters on the horizon. Spin-off allows shareholders to benefit from a standalone Alcon and a Novartis with capital and management attention fully focused on medicines.
On April 9, 2019, Alcon completed a 100% spin-off from Novartis. [4][16][17] The new standalone company is worth up to 28 billion Swiss francs. [18] In November 2021, Alcon announced it would acquire Ivantis and their glaucoma surgery stent technology for at least $475 million. [19]
Basel, March 22, 2019 - Novartis today confirmed that certain important conditions precedent for the 100% spin-off of the Alcon eye care business have been met, including receipt of certain necessary authorizations and rulings. Completion of the transaction, by way of a distribution of a dividend in kind to Novartis shareholders and ADR ...
アルコンでは2万人以上の従業員が日々、革新的な製品、アイケア専門家とのパートナーシップ、質の高いアイケアの提供に努めています。. 詳細については www.alcon.co.jp をご覧ください。. ノバルティスからの分離が完了 スイス証券取引所（SIX）および ...
Alcon becomes an independent, publicly-traded company, after spinning off from Novartis. Alcon offers the widest array of contact lenses and surgical and ocular health products in the industry 2019
GENEVA--(BUSINESS WIRE)--Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced its debut as an independent, publicly traded company and the completion of its separation from Novartis. The company’s shares begin trading today on the SIX Swiss Exchange and New York Stock Exchange (NYSE) under the ...
New York, November 27, 2018 — Alcon, the eye care division of Novartis, will today hold its first Capital Markets Day for investors and analysts in relation to the previously-announced intention of Novartis to execute a tax-neutral, 100% spinoff of the Alcon business.
アルコン・インコーポレーテッド（Alcon, Inc.、SIX: ALC、NYSE: ALC）は、コンタクトレンズなど眼科領域の医療機器や薬剤を扱う国際企業である。 本項は日本法人の 日本アルコン株式会社 (ALCON JAPAN LTD.)